期刊文献+

腺相关病毒的生产方式及其在基因治疗中的应用 被引量:6

The Production Method of Adeno-associated Virus and its Application in Gene Therapy
下载PDF
导出
摘要 随着基因治疗产品不断得到批准用于临床研究,基因治疗相关的病毒载体也受到广泛关注,其中腺相关病毒载体因其低致病性、低免疫原性、宿主范围广泛且稳定表达等独特优势成为最有前景的病毒载体,广泛应用于临床研究,目前已有2种重组腺相关病毒载体的药品得到批准且效果显著,但由于大规模生产技术的缺乏限制了重组腺相关病毒载体的研究和广泛应用。就腺相关病毒的结构和功能、载体的生产方式及其现阶段在基因治疗中的应用进行了综述,以期为今后以腺相关病毒为载体的基因治疗大规模应用于市场提供参考。 With the continuous approval of gene therapy products into the clinical research, the viral vectors which are used for gene therapy have attracted extensive attention. Adeno-associated virus is the most promising viral vector of many other viral vectors because of its low pathogenicity, low immunogenicity and the advantage of the host range and stable expression. It has gotten a wide range of applications in clinical research. Currently, two drugs related to recombinant adenovirus vectors have approved for clinical application with significant effects. But its lacking of mass production technology limits its research and wide applications. This review summarized the structure and function of adeno-associated virus, its production mode and recent clinical application in gene therapy to support reference for its widely application in the market.
作者 杜梦潭 刘兴健 胡小元 张志芳 李轶女 DU Mengtan;LIU Xingjian;HU Xiaoyuan;ZHANG Zhifang;LI Yinv(Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China)
出处 《生物技术进展》 2019年第4期326-331,共6页 Current Biotechnology
基金 国家自然科学基金项目(31872430 31670156)资助
关键词 腺相关病毒 基因治疗 杆状病毒表达系统 脂蛋白脂肪酶缺乏症 人类视网膜疾病 adeno-associated virus gene therapy baculovirus expression system LPLD human retinal disease
  • 相关文献

参考文献3

二级参考文献56

  • 1王启钊,吕颖慧,许瑞安.基因治疗用腺相关病毒载体的剂量效应与剂量控制(英文)[J].中国临床药理学与治疗学,2008,13(10):1182-1194. 被引量:2
  • 2Atchison R W, Casto B C, Hammon W M. Adenovi-rus-associated defective virus particles[J]. Science, 1965,149:754-756.
  • 3Lock M, Alvira M, Vandenberghe L H, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale[J]. Hum Gene Ther, 2010,21(10): 1259-1271.
  • 4Manno C S, Pierce G F, Arruda V R, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response[J]. Nat Med, 2006, 12(3): 342-347.
  • 5Mingozzi F, Meulenberg J J, Hui D J, et al. AAV-l-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells[J]. Blood, 2009,114( 10):2077 -2086.
  • 6Flotte T R, Trapnell B C, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha(1)-antitrypsin: interim results[J]. Hum Gene Ther, 2011,22(10):1239-1247.
  • 7Sonntag F, Schmidt K, Kleinschmidt J A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus[J]. Proc Natl Acad Sci USA, 2010,107(22):10220-10225.
  • 8Coura R D, Nardi N B. A role for adeno-associated viral vectors in gene therapy[J]. Genet Mol Biol, 2008,31(1):1-11.
  • 9Daya S, Berns K I. Gene therapy using adeno-associated virus vectors[J]. Clin Microbiol Rev, 2008,21(4):583-593.
  • 10Girod A, Wobus C E, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholi-pase A2 domain required for virus infectivity[J]. J Gen Virol, 2002,83:973-978.

共引文献13

同被引文献17

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部